4 companies in Anthos Capital's investment portfolio.
Back to Anthos Capital profile“Invests in growth-stage healthcare and technology companies with focus on transformative healthcare solutions.”
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Genomic diagnostics company that develops molecular tests to help physicians make treatment decisions for patients with thyroid, lung, and breast diseases.
Anthos Capital has built a portfolio of 4 companies across 1 sector, including Biotech.
The portfolio reflects investments across the IPO stage, showing Anthos Capital's approach to supporting companies at a focused stage of development.
Anthos Capital has invested in 4+ companies across 1 different sectors.
Anthos Capital's portfolio spans Biotech. This diversification reflects the firm's broad investment thesis and sector expertise.
Anthos Capital invests across the IPO stage. Their portfolio includes companies at various points in their growth journey.
Archstone
Fund admin, LP portal, capital calls, distributions, and reporting in one place. Purpose-built for emerging fund managers. Starting at $297/mo.
See Archstone